pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Cagrisema
drug
save

(cagrilintide + semaglutide)

pre_registrationupdated 6mo ago
by Novo Nordisk AS
community read0 votes

indications

indications
Obesity

all catalysts(0)

nothing on the calendar yet

Trials studying (cagrilintide + semaglutide)

  • phase1A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Dietactive not recruitingn=80
  • phase1A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Single Doses of Different Versions of Injectable CagriSema in Adults With Overweight or Obesitycompletedn=18
  • phase3A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weightrecruitingn=2,500
  • phase3A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termactive not recruitingn=609
  • phase3A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetesnot yet recruitingn=80
  • phase2A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetesnot yet recruitingn=400
  • phase3A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weightnot yet recruitingn=1,400
  • phase2A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathyactive not recruitingn=142

News(10)

  • Novo’s consumer push gains momentum with Wegovy pill, CagriSema on deck
    LAS VEGAS — When Ed Cinca returned to Novo after four years away, he barely recognized the place. “I think the building’s the same, but that’s about it,” Cinca, Novo’s senior vice president of mark…
    endpoints · 19h ago
  • Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
    The FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…
    biospace · 1d ago
  • Novo’s CagriSema drives more than 20% weight loss at lower doses
    As Novo awaits an FDA decision for its next-gen obesity asset, the company has presented more data at ObesityWeek that could help buoy sentiment on the amylin/GLP-1 combination that disappointed in…
    biospace · 2d ago
  • Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026
    ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…
    biospace · 6d ago
  • Novo gets much-needed lift as Wegovy pill tops Wall Street forecasts
    The drug’s third-quarter sales numbers came in well above consensus estimates, widening Novo’s early edge over Eli Lilly in the latest battleground for weight loss medicines.
    biopharma_dive · 14d ago
  • Novo won't launch CagriSema in Europe for 'a couple of years,' CFO says
    Novo won't launch its big obesity hope CagriSema in Europe for another “couple of years,” Novo’s outgoing CFO Karsten Munk Knudsen told Endpoints News in a Wednesday interview. “For CagriSema, the…
    endpoints · 15d ago
  • Novo’s CEO still looking for deals to ‘close some of the gaps,’ as misfires hit profits
    Novo’s CEO has told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline, as the Big Pharma reports billions of dollars in impairment charges from a s…
    fiercebiotech · 15d ago
  • Novo’s CagriSema achieves 25% weight loss in women, driven by younger patients
    Posthoc analyses in women divided by menopausal status show how Novo’s next-generation GLP-1 drug affects key cohorts of patients.
    biospace · 29d ago
  • STAT+: Pharmalittle: We’re reading about drug launch prices, an AstraZeneca AI deal, and more
    The median net price for newly launched medicines, when adjusted for inflation and manufacturer discounts, rose by 35% from 2022 to 2025.
    stat · 1mo ago
  • Should amylin have been obesity therapeutics’ primary target from the start?
    While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 year…
    biospace · 1mo ago
view all news mentions →
brand
Cagrisema
generic
(cagrilintide [INN] + semaglutide)
indication
Obesity
phase
pre_registration
Data sources
ClinicalTrials.gov
last refreshed 3h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?